A study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer

Trial Identifier:	D0818R00008
Sponsor:	AstraZeneca
Collaborator:	Merck
NCTID::	NCT05775549
Start Date:	July 2023
Primary Completion Date:	September 2023
Study Completion Date:	September 2023
Condition:	Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.